Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies

Expert Opinion on Biological Therapy

Volumn 16, Issue 12, 2016, Pages 1455-1468

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer s disease; bispecific antibody; Blood brain barrier; brain drug delivery; CSF

Indexed keywords

ADALIMUMAB; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; BAPINEUZUMAB; BETA SECRETASE; BETA SECRETASE 1; BETA SECRETASE 1 INHIBITOR; BETA SECRETASE INHIBITOR; BISPECIFIC ANTIBODY; DIAZEPAM; ETANERCEPT; FC RECEPTOR; IMMUNOGLOBULIN G; INSULIN RECEPTOR; MEMBRANE PROTEIN; METABOTROPIC RECEPTOR 1; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; CD71 ANTIGEN; INSR PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PEPTIDE; SECRETASE;

ACTIVE TRANSPORT; ALZHEIMER DISEASE; AMINO ACID TRANSPORT; AMINO TERMINAL SEQUENCE; AMYLOID PLAQUE; ANTIBODY ENGINEERING; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BRAIN; BRAIN BLOOD VESSEL; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; CROSS REACTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; GENE TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR MODEL; NEUROIMAGING; NEURORADIOLOGY; NONHUMAN; PHARMACOKINETIC PARAMETERS; PLASMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN DOMAIN; RECEPTOR MEDIATED TRANSPORT; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BIOMEDICAL ENGINEERING; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ASPARTIC ACID ENDOPEPTIDASES; BIOLOGICAL TRANSPORT; BIOMEDICAL ENGINEERING; BLOOD-BRAIN BARRIER; HUMANS; PEPTIDES; RECEPTOR, INSULIN; RECEPTORS, TRANSFERRIN;

EID: 84994431107     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1230195     Document Type: Review

References (103)

1. K.Han, M.Ren, W.Wick, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma:a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014 May;16(5):696–706. DOI:10.1093/neuonc/not236
2. H.-L.Liu, P.-H.Hsu, C.-Y.Lin, et al. Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology. 2016 May 18:152444. DOI:10.1148/radiol.2016152444
3. D.Cadavid, S.Jurgensen, S.Lee Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013;8(1):e53297. DOI:10.1371/journal.pone.0053297
4. B.Engelhardt, C.Coisne. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS. 2011;8(1):4. DOI:10.1186/2045-8118-8-4
5. W.M.Pardridge. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clin Pharmacol Ther. 2015 Apr;97(4):347–361. DOI:10.1002/cpt.18
6. W.M.Pardridge. Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev. 1986 Aug;7(3):314–330. DOI:10.1210/edrv-7-3-314
7. W.M.Pardridge, J.L.Buciak, P.M.Friden. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther. 1991 Oct;259(1):66–70.
8. W.M.Pardridge, Y.S.Kang, J.L.Buciak, et al. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res. 1995 Jun;12(6):807–816.
9. W.M.Pardridge, R.J.Boado. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 2012;503:269–292. DOI:10.1016/B978-0-12-396962-0.00011-2
10. J.D.Sengillo, E.A.Winkler, C.T.Walker, et al. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer’s disease. Brain Pathol. 2013 May;23(3):303–310. DOI:10.1111/bpa.12004
11. Z.Zhao, A.R.Nelson, C.Betsholtz, et al. Establishment and dysfunction of the blood-brain barrier. Cell. 2015 Nov 19;163(5):1064–1078.
12. J.K.Ryu, J.G.McLarnon. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J Cell Mol Med. 2009 Sep;13(9A):2911–2925. DOI:10.1111/j.1582-4934.2008.00434.x
13. K.Hultman, S.Strickland, E.H.Norris. The APOE varepsilon4/varepsilon4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer’s disease patients. J Cereb Blood Flow Metab. 2013 Aug;33(8):1251–1258. DOI:10.1038/jcbfm.2013.76
14. M.R.Halliday, S.V.Rege, Q.Ma, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. J Cereb Blood Flow Metab. 2016 Jan;36(1):216–227. DOI:10.1038/jcbfm.2015.44
15. D.G.Munoz, T.Erkinjuntti, S.Gaytan-Garcia, et al. Serum protein leakage in Alzheimer’s disease revisited. Ann N Y Acad Sci. 1997 Sep;26(826):173–189. DOI:10.1111/j.1749-6632.1997.tb48469.x
16. N.G.Harris, V.Gauden, P.A.Fraser, et al. MRI measurement of blood-brain barrier permeability following spontaneous reperfusion in the starch microsphere model of ischemia. Magn Reson Imaging. 2002 Apr;20(3):221–230.
17. A.Montagne, S.R.Barnes, M.D.Sweeney, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015 Jan 21;85(2):296–302.
18. H.J.van de Haar, S.Burgmans, J.F.Jansen, et al. Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology. 2016 May 31:152244. DOI:10.1148/radiol.2016152244
19. N.L.Schlageter, R.E.Carson, S.I.Rapoport. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography. J Cereb Blood Flow Metab. 1987 Feb;7(1):1–8. DOI:10.1038/jcbfm.1987.1
20. S.Akoudad, F.J.Wolters, A.Viswanathan, et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol. 2016 Aug 1;73(8):934–943.
21. B.V.Zlokovic. Cerebrovascular permeability to peptides:manipulations of transport systems at the blood-brain barrier. Pharm Res. 1995 Oct;12(10):1395–1406.
22. H.J.Frank, T.Jankovic-Vokes, W.M.Pardridge, et al. Enhanced insulin binding to blood-brain barrier in vivo and to brain microvessels in vitro in newborn rabbits. Diabetes. 1985 Aug;34(8):728–733.
23. S.J.Giddings, J.Chirgwin, M.A.Permutt. Evaluation of rat insulin messenger RNA in pancreatic and extrapancreatic tissues. Diabetologia. 1985 Jun;28(6):343–347.
24. K.R.Duffy, W.M.Pardridge. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 1987 Sep 8;420(1):32–38.
25. J.B.Fishman, J.B.Rubin, J.V.Handrahan, et al. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res. 1987;18(2):299–304. DOI:10.1002/jnr.490180206
26. W.M.Pardridge, J.Eisenberg, J.Yang. Human blood-brain barrier transferrin receptor. Metabolism. 1987 Sep;36(9):892–895.
27. W.M.Pardridge. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv. 2015 Feb;12(2):207–222. DOI:10.1517/17425247.2014.952627
28. H.J.Lee, B.Engelhardt, J.Lesley, et al. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000 Mar;292(3):1048–1052.
29. R.J.Boado, Y.Zhang, Y.Wang, et al. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng. 2009Mar1;102(4):1251–1258. DOI:10.1002/bit.22135• Genetic engineering of a recombinant chimeric monoclonal antibody against the mouse transferrin receptor that comprises the rat variable regions and mouse constant region.
30. Q.-H.Zhou, R.J.Boado, W.M.Pardridge. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. J Drug Target. 2012 Sep;20(8):715–719. DOI:10.3109/1061186X.2012.712132
31. M.J.Coloma, H.J.Lee, A.Kurihara, et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res. 2000 Mar;17(3):266–274.
32. R.J.Boado, Y.Zhang, Y.Zhang, et al. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007 Feb 1;96(2):381–391.
33. S.Ohtsuki, Y.Uchida, Y.Kubo, et al. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development:methodology, advantages, strategy, and prospects. J Pharm Sci. 2011 Sep;100(9):3547–3559. DOI:10.1002/jps.22612• Liquid chromatography/mass spectrometry methodology for quantitative measurements of the expression of receptor and transporter proteins in capillaries isolated from animal or human brain.
34. Y.Uchida, S.Ohtsuki, Y.Katsukura, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011 Apr;117(2):333–345. DOI:10.1111/j.1471-4159.2011.07208.x
35. S.Agarwal, Y.Uchida, R.K.Mittapalli, et al. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos. 2012 Jun;40(6):1164–1169. DOI:10.1124/dmd.112.044719
36. Y.Hoshi, Y.Uchida, M.Tachikawa, et al. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J Pharm Sci. 2013 Sep;102(9):3343–3355. DOI:10.1002/jps.23575
37. D.Triguero, J.Buciak, W.M.Pardridge. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem. 1990 Jun;54(6):1882–1888.
38. D.R.Greaves, S.Gordon. The macrophage scavenger receptor at 30 years of age:current knowledge and future challenges. J Lipid Res. 2009 Apr;50(Suppl):S282–S286. DOI:10.1194/jlr.R800066-JLR200
39. B.V.Zlokovic. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011 Dec;12(12):723–738. DOI:10.1038/nrn3114
40. X.Tian, S.P.S.S.Nyberg, J.Madsen, et al. LRP-1-mediated intracellular antibody delivery to the central nervous system. Sci Rep. 2015;5:11990. DOI:10.1038/srep11990
41. S.E.Storck, S.Meister, J.Nahrath, et al. Endothelial LRP1 transports amyloid-beta(1-42) across the blood-brain barrier. J Clin Invest. 2016 Jan;126(1):123–136. DOI:10.1172/JCI81108
42. M.Demeule, J.C.Currie, Y.Bertrand, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008 Aug;106(4):1534–1544. DOI:10.1111/j.1471-4159.2008.05492.x
43. W.M.Pardridge. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012 Nov;32(11):1959–1972. DOI:10.1038/jcbfm.2012.126
44. B.Nazer, S.Hong, D.J.Selkoe. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis. 2008 Apr;30(1):94–102. DOI:10.1016/j.nbd.2007.12.005
45. A.Muruganandam, J.Tanha, S.Narang, et al. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 2002 Feb;16(2):240–242. DOI:10.1096/fj.01-0343fje
46. G.K.Farrington, N.Caram-Salas, A.S.Haqqani, et al. A novel platform for engineering blood-brain barrier-crossing bispecific biologics. FASEB J. 2014 Nov;28(11):4764–4778. DOI:10.1096/fj.14-253369
47. C.I.Webster, N.Caram-Salas, A.S.Haqqani, et al. Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1. FASEB J. 2016 May;30(5):1927–1940. DOI:10.1096/fj.201500078• BBB-penetrating bispecific antibody formed by fusion of an ScFv transporter antibody against the FC5 orphan receptor and a therapeutic antibody targeting the metabotropic glutamate receptor-1.
48. A.S.Haqqani, N.Caram-Salas, W.Ding, et al. Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. Mol Pharm. 2013 May 6;10(5):1542–1556.
49. V.A.van der Mark, D.R.deWaart, K.S.Ho-Mok, et al. The lipid flippase heterodimer ATP8B1-CDC50A is essential for surface expression of the apical sodium-dependent bile acid transporter (SLC10A2/ASBT) in intestinal Caco-2 cells. Biochim Biophys Acta. 2014;1842:2378–2386. DOI:10.1016/j.bbadis.2014.09.003
50. W.M.Pardridge. Blood-brain barrier endogenous transporters as therapeutic targets:a new model for small molecule CNS drug discovery. Expert Opin Ther Targets. 2015;19(8):1059–1072. DOI:10.1517/14728222.2015.1042364
51. R.J.Boado, J.Y.Li, M.Nagaya, et al. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci. 1999;96:12079–12084.
52. Y.J.Zuchero, X.Chen, N.Bien-Ly, et al. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron. 2016 Jan 6;89(1):70–82.
53. J.Fort, L.R.Dela Ballina, H.E.Burghardt, et al. The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane. J Biol Chem. 2007;282:31444–31452. DOI:10.1074/jbc.M704524200
54. F.C.Thomas, K.Taskar, V.Rudraraju, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009 Nov;26(11):2486–2494. DOI:10.1007/s11095-009-9964-5
55. D.Karkan, C.Pfeifer, T.Z.Vitalis, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One. 2008;3(6):e2469. DOI:10.1371/journal.pone.0002469
56. D.Deng, C.Xu, P.Sun, et al. Crystal structure of the human glucose transporter GLUT1. Nature. 2014 Jun 5;510(7503):121–125.
57. E.A.Winkler, Y.Nishida, A.P.Sagare, et al. GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015 Apr;18(4):521–530. DOI:10.1038/nn.3966
58. Y.Kubo, S.Ohtsuki, Y.Uchida, et al. Quantitative determination of luminal and abluminal membrane distributions of transporters in porcine brain capillaries by plasma membrane fractionation and quantitative targeted proteomics. J Pharm Sci. 2015 Sep;104(9):3060–3068. DOI:10.1002/jps.24398
59. W.M.Pardridge, P.L.Golden, Y.S.Kang, et al. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem. 1997 Mar;68(3):1278–1285.
60. J.-Z.Wang, N.Xiao, Y.-Z.Zhang, et al. Mfsd2a-based pharmacological strategies for drug delivery across the blood-brain barrier. Pharmacol Res. 2016 Feb;104:124–131. DOI:10.1016/j.phrs.2015.12.024
61. E.M.Cornford, L.D.Braun, W.H.Oldendorf. Developmental modulations of blood-brain barrier permeability as an indicator of changing nutritional requirements in the brain. Pediatr Res. 1982 Apr;16(4 Pt 1):324–328.
62. J.K.Atwal, Y.Chen, C.Chiu, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med. 2011 May 25;3(84):84ra43.
63. B.Bohrmann, K.Baumann, J.Benz, et al. Gantenerumab:a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49–69. DOI:10.3233/JAD-2011-110977
64. W.M.Pardridge. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016 Jul;13(7):963–975. DOI:10.1517/17425247.2016.1171315
65. H.Reiber. Proteins in cerebrospinal fluid and blood:barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci. 2003;21(3–4):79–96.
66. E.Urich, S.E.Lazic, J.Molnos, et al. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One. 2012;7(5):e38149. DOI:10.1371/journal.pone.0038149
67. W.M.Pardridge, D.Triguero, J.Yang, et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther. 1990 May;253(2):884–891.
68. F.Panza, V.Solfrizzi, B.P.Imbimbo, et al. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease:the point of no return? Expert Opin Biol Ther. 2014 Oct;14(10):1465–1476. DOI:10.1517/14712598.2014.935332• Reviews failure of a therapeutic antibody for Alzheimer’s disease, which entered clinical trials without engineering to enable BBB transport of the therapeutic antibody.
69. P.Seubert, R.Barbour, K.Khan, et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis. 2008;5(2):65–71. DOI:10.1159/000112834
70. F.Bard, M.Fox, S.Friedrich, et al. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol. 2012;238:38–43. DOI:10.1016/j.expneurol.2012.07.022
71. R.J.Boado, Q.H.Zhou, J.Z.Lu, et al. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm. 2010 Feb 1;7(1):237–244.
72. D.J.Greenblatt, V.H.Sethy. Benzodiazepine concentrations in brain directly reflect receptor occupancy:studies of diazepam, lorazepam, and oxazepam. Psychopharmacology (Berl). 1990;102(3):373–378.
73. R.K.Sumbria, Q.-H.Zhou, E.K.-W.Hui, et al. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol Pharm. 2013;10:1425–1431. DOI:10.1021/mp400004a
74. J.S.Marvin, Z.Zhu. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin. 2005 Jun;26(6):649–658. DOI:10.1111/j.1745-7254.2005.00119.x
75. Y.J.Yu, Y.Zhang, M.Kenrick, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011 May 25;3(84):84ra44.
76. J.Niewoehner, B.Bohrmann, L.Collin, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014 Jan 8;81(1):49–60. DOI:10.1016/j.neuron.2013.10.061• BBB-penetrating bispecific antibody formed by fusion of a single-chain Fab transporter antibody against the mouse transferrin receptor and a therapeutic antibody targeting the Abeta amyloid peptide of Alzheimer’s disease.
77. C.Wu, H.Ying, C.Grinnell, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007 Nov;25(11):1290–1297. DOI:10.1038/nbt1345
78. R.J.Boado, Y.Zhang, Y.Zhang, et al. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem. 2007 Mar-Apr;18(2):447–455. DOI:10.1021/bc060349x• First BBB-penetrating bispecific antibody formed by fusion of an ScFv antibody against the Abeta amyloid peptide to the carboxyl terminus of the heavy chain of a chimeric monoclonal antibody against the human insulin receptor.
79. M.J.Coloma, S.L.Morrison. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997;15(2):159–163. DOI:10.1038/nbt0297-159
80. Y.Zhang, W.M.Pardridge. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol. 2001 Mar 1;114(1–2):168–172.
81. Y.Zhang, W.M.Pardridge. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem. 2001 Mar;76(5):1597–1600.
82. H.F.Cserr, D.N.Cooper, P.K.Suri, et al. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol. 1981 Apr;240(4):F319–F328.
83. F.Schlachetzki, C.Zhu, W.M.Pardridge. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem. 2002 Apr;81(1):203–206.
84. A.S.De Groot, L.Moise, J.A.McMurry, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008 Oct 15;112(8):3303–3311.
85. R.K.Sumbria, E.K.Hui, J.Z.Lu, et al. Disaggregation of amyloid plaque in brain of Alzheimer’s disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol Pharm. 2013Sep3;10(9):3507–3513. DOI:10.1021/mp400348n• AD mice were treated by daily subcutaneous injection for 12 consecutive weeks with a BBB-penetrating bispecific antibody formed by fusion of an ScFv antibody to the carboxyl terminus of a chimeric monoclonal antibody against the mouse transferrin receptor.
86. R.J.Boado, J.Z.Lu, E.K.-W.Hui, et al. IgG-single chain Fv fusion protein therapeutic for Alzheimer’s disease:expression in CHO cells and pharmacokinetics and brain delivery in the Rhesus monkey. Biotechnol Bioeng. 2010;105:627–635. DOI:10.1002/bit.22576
87. Q.H.Zhou, R.J.Boado, E.K.Hui, et al. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos. 2011 Jul;39(7):1149–1154. DOI:10.1124/dmd.111.038349
88. Y.J.Yu, J.K.Atwal, Y.Zhang, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014 Nov 5;6(261):261ra154. DOI:10.1126/scitranslmed.3009835• Primate study of a BBB-penetrating bispecific antibody formed by fusion of a therapeutic antibody against BACE1 and a transporter antibody against the human transferrin receptor shows the advantage of increasing the affinity of the transporter antibody for the target BBB receptor.
89. L.R.Walus, W.M.Pardridge, R.M.Starzyk, et al. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies. J Pharmacol Exp Ther. 1996 May;277(2):1067–1075.• Early study showing the transport through the BBB in vivo in the primate of a monoclonal antibody targeting the human transferrin receptor.
90. M.L.Cucchiaroni, M.T.Viscomi, G.Bernardi, et al. Metabotropic glutamate receptor 1 mediates the electrophysiological and toxic actions of the cycad derivative beta-N-Methylamino-L-alanine on substantia nigra pars compacta DAergic neurons. J Neurosci. 2010 Apr 14;30(15):5176–5188.
91. O.El-Kouhen, S.G.Lehto, J.B.Pan, et al. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances:effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol. 2006 Nov;149(6):761–774. DOI:10.1038/sj.bjp.0706877
92. D.Sehlin, X.T.Fang, L.Cato, et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease. Nat Commun. 2016;7:10759. DOI:10.1038/ncomms10759• First study of a BBB-penetrating bispecific antibody used as a neurodiagnostic agent for in vivo imaging of the amyloid burden in brain in a mouse model of Alzheimer’s disease.
93. D.F.Wong, P.B.Rosenberg, Y.Zhou, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010 Jun;51(6):913–920. DOI:10.2967/jnumed.109.069088
94. G.Bedse, F.Di Domenico, G.Serviddio, et al. Aberrant insulin signaling in Alzheimer’s disease:current knowledge. Front Neurosci. 2015;9:204. DOI:10.3389/fnins.2015.00204
95. C.M.Morris, J.M.Candy, J.M.Kerwin, et al. Transferrin receptors in the normal human hippocampus and in Alzheimer’s disease. Neuropathol Appl Neurobiol. 1994 Oct;20(5):473–477.
96. R.S.Black, R.A.Sperling, B.Safirstein, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198–203. DOI:10.1097/WAD.0b013e3181c53b00
97. S.Segaert. Etanercept, improved dosage schedules and combinations in the treatment of psoriasis:an update. J Inflamm Res. 2009;2:29–36.
98. R.B.Pepinsky, L.Silvian, S.A.Berkowitz, et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci. 2010 May;19(5):954–966. DOI:10.1002/pro.372
99. N.B.Lawand, N.E.Saade, O.M.El-Agnaf, et al. Targeting alpha-synuclein as a therapeutic strategy for Parkinson’s disease. Expert Opin Ther Targets. 2015;19(10):1351–1360. DOI:10.1517/14728222.2015.1062877
100. A.R.Marques, E.Teixeira, J.Diamond, et al. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat. 2009 Mar;114(2):223–232. DOI:10.1007/s10549-008-0002-9
101. M.Kinoshita, N.McDannold, F.A.Jolesz, et al. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11719–11723.
102. D.Ben-Nathan, I.Huitinga, S.Lustig, et al. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol. 1996;141(3–4):459–469.
103. T.Oliphant, M.Engle, G.E.Nybakken, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005 May;11(5):522–530. DOI:10.1038/nm1240